Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TP53 over exp |
| Therapy | HLA-A2 p53:264-272 vaccine |
| Indication/Tumor Type | ovarian cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 over exp | ovarian cancer | predicted - sensitive | HLA-A2 p53:264-272 vaccine | Phase I | Actionable | In a Phase I trial, the HLA-A2 p53:264-272 vaccine demonstrated safety and preliminary efficacy in patients with TP53 overexpressing ovarian cancer, resulting in a progression-free survival of 5.5 months and an overall survival of 40.4 months (PMID: 21927947). | 21927947 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (21927947) | A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. | Full reference... |